A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...
Chronic graft-versus-host disease (GVHD) is a cause of late morbidity and mortality after allogeneic stem cell transplant.
Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...
An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...
Somatostatin analogs (SSAs) like octreotide LAR and lanreotide are essential in managing NETs. Standard practice involves ...
A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving ...
Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.
CUTNETs aims to improve surgical evidence for NETs by identifying high-risk patients and developing resectability criteria. Collaboration is essential due to the uncommon nature of NETs and the need ...
At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback